The UK MHRA has granted marketing authorisation to Bavarian Nordic's Vimkunya vaccine for preventing the chikungunya virus.

Whilst 2025 outlooks include cost impact from existing tariffs, companies have not adjusted their guidance for future ...

The US HHS has launched a $500m initiative to accelerate the development of universal vaccines targeting viruses with ...

As scientists explore treating genetic disorders before birth, the promise of foetal gene therapy is growing—but there are ...

D Molecular Therapeutics (4DMT) has received the regenerative medicine advanced therapy (RMAT) designation from the FDA for ...

Repare Therapeutics has entered into an out-licensing agreement with Canadian biotechnology firm DCx for discovery platforms ...

The post-traumatic stress disorder (PTSD) market is expected to grow at a high compound annual growth rate of 16.1% from ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

Though optimistic, speakers at the recent LSX World Congress in London, UK, recognised that recent turbulence in the wake of ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...